BAGSVAERD, DENMARK--(Marketwire - April 23, 2012) -
At Novo Nordisk's Annual General Meeting on 21 March 2012, it was decided
to
reduce the company's B share capital from DKK 472,512,800 to DKK
452,512,800 by cancellation of part of the company's portfolio of own B
shares
at a nominal value of DKK 20,000,000 divided into 20,000,000 B shares of
DKK 1
each.
Today, Novo Nordisk has registered the implementation of the reduction of
the
share capital with the Danish Business Authority and cancelled nominally
DKK
20,000,000 B shares. After the reduction of the share capital, the
company's
share capital is nominally DKK 560,000,000, which is divided into an A
share
capital of nominally DKK 107,487,200 and a B share capital of nominally DKK
452,512,800.
The reduction in the share capital will not affect Novo Nordisk's share
repurchase programme which will continue as previously announced.
Novo Nordisk is a global healthcare company with 89 years of innovation and
leadership in diabetes care. The company also has leading positions within
haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 32,700
employees in
75 countries, and markets its products in more than 190 countries. Novo
Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs
are
listed on the New York Stock Exchange (NVO). For more information, visit
novonordisk.com.
Company Announcement no 26 / 2012
Read the Articles of Association in PDF format:
http://hugin.info/2013/R/1604975/508019.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1604975]
